Skip to content

Author

Marion Wobser

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma in Europe.

In advanced cutaneous T-cell lymphoma (CTCL), allogeneic stem cell transplant is the only curative option, but many patients are ineligible and relapse after systemic therapy, requiring retreatment with prior therapies. Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody drug conjugated with monomethyl auristati...

C. Mitteldorf, A. de Masson, M. Beylot-Barry et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.